NDA 021735 · Fougera
Terconazole
Terconazole · Vaginal · Azole Antifungal
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Oct 1, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
5 Phase 3, 0 recruiting
FAERS reports
831
456 serious, 23 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 28, 2026.
Terconazole Vaginal Cream, is indicated for the treatment of vulvovaginal candidiasis in adult females. Terconazole Vaginal Cream is an azole antifungal indicated for the treatment of vulvovaginal candidiasis in adult females. ( 1 )
Mechanism: Terconazole is an antifungal agent [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TERCONAZOLE · TERCONAZOLE 0.8% · CREAM, VAGINAL · Prescription · TE BX
Clinical trials
Interventional ClinicalTrials.gov studies with "Terconazole" as an intervention, any sponsor and status, largest first.
- Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal CandidiasisPivotal-lookingCompleted
Padagis LLCIndustry
NCT00803738 · 572 participants · Start Dec 2002 · Primary completion Dec 2003
Drug: Terconazole Vaginal Suppository; Terazol Vaginal Suppository · For: Vulvovaginal Candidiasis
- Multi-Center Study of New Medications to Treat Vaginal InfectionsPivotal-lookingCompleted
Curatek Pharmaceuticals, LLCIndustry
NCT02308007 · 475 participants · Start Jun 2015 · Primary completion Jun 2018
Drug: Terconazole; Metronidazole and 1 more · For: Vaginal Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 51 sites in all
- Multi-Center Study of New Medications to Treat Vaginal InfectionsPivotal-lookingCompleted
Curatek Pharmaceuticals, LLCIndustry
NCT02308046 · 212 participants · Start Jun 2015 · Primary completion Jun 2017
Drug: Terconazole; Placebo · For: Vaginal Infection
Sites: Birmingham, Alabama; Chandler, Arizona; Scottsdale, Arizona · 41 sites in all
- Multi-Center Study of New Medications to Treat Vaginal InfectionsPivotal-lookingCompleted
Curatek Pharmaceuticals, LLCIndustry
NCT02308033 · 204 participants · Start Jun 2015 · Primary completion Jun 2017
Drug: Metronidazole; Gel vehicle · For: Vaginal Infection
Sites: Birmingham, Alabama; Scottsdale, Arizona; Jonesboro, Arkansas · 35 sites in all
Janssen-Cilag, S.A.Johnson & Johnson (Janssen) (JNJ)
NCT01867164 · 160 participants · Start Dec 2007 · Primary completion Dec 2008
Drug: Gynoclin V; Vagitrol V · For: Vaginitis; Infectious Vaginosis
Sites: DF, Mexico; Mexico City, Mexico
- Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal CandidiasisPivotal-lookingCompleted
Peking University Shenzhen HospitalAcademic, hospital or other
NCT02180100 · 140 participants · Start Aug 2013 · Primary completion Jun 2014
Drug: Terconazole Vaginal Suppository; Fluconazole · For: Vulvovaginal Candidiasis
Sites: Shenzhen, China
- In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal ProductsPivotal-lookingCompleted
CONRADAcademic, hospital or other
NCT01813162 · 101 participants · Start Dec 2013 · Primary completion Dec 2014
Drug: Tenofovir 1% gel; Vaginal product · For: HIV Prevention
Sites: San Francisco, California; The Bronx, New York
Hatem AbuHashimAcademic, hospital or other
NCT04208555 · 76 participants (planned) · Start Jan 15, 2020 · Primary completion Feb 28, 2021
Drug: Boric Acid Vaginal Suppository; Terconazole Vaginal Suppository · For: Vulvovaginal Candidiasis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain96
- chronic kidney disease68
- drug ineffective57
- nausea50
- anxiety49
- headache46
- urinary tract infection43
- fatigue40
- product quality issue40
- acute kidney injury37
- emotional distress36
- pain in extremity33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 8 |
| 2009 | 13 |
| 2010 | 14 |
| 2011 | 30 |
| 2012 | 23 |
| 2013 | 40 |
| 2014 | 31 |
| 2015 | 41 |
| 2016 | 55 |
| 2017 | 40 |
| 2018 | 88 |
| 2019 | 99 |
| 2020 | 86 |
| 2021 | 62 |
| 2022 | 48 |
| 2023 | 40 |
| 2024 | 27 |
| 2025 | 37 |
| 2026 | 41 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Terconazole (Terconazole)
2024 spending
$3.7M
Beneficiaries
87,657
128,154 claims
Per beneficiary
$42
$1.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,426,074 |
| 2021 | $4,182,669 |
| 2022 | $4,192,495 |
| 2023 | $4,059,954 |
| 2024 | $3,704,524 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatment for vaginal candidiasis (thrush) in pregnancy.
Young GL, Jewell D · Cochrane Database Syst Rev 2001 · Systematic Review
- Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison.
Corson SL, Kapikian RR, Nehring R · J Reprod Med 1991 · Clinical Trial, Comparative Study
- Prevention of recurrent vaginal candidiasis with weekly terconazole cream.
Stein GE, Mummaw NL, Schooley SL · Ann Pharmacother 1996 · Clinical Trial, Research Support, Non-U.S. Gov't
- [Terconazole in vaginal candidiasis. A comparative study].
Llaca Rodríguez V, Carrión Tizcareño H, Arguelles Domenzain P · Ginecol Obstet Mex 1990 · Clinical Trial, Comparative Study
- Chromatographic and electrophoretic techniques used in the analysis of triazole antifungal agents-a review.
Ekiert RJ, Krzek J, Talik P · Talanta 2010 · Systematic Review
- Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis.
Kjaeldgaard A · Pharmatherapeutica 1986 · Clinical Trial, Comparative Study
Sponsor: Fougera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.